Open Access

HPV infection and triple-negative breast cancers: an Italian case-control study

  • Andrea Fausto Piana1,
  • Giovanni Sotgiu1, 3Email author,
  • Maria Rosaria Muroni2,
  • Paolo Cossu-Rocca2, 4,
  • Paolo Castiglia1 and
  • Maria Rosaria De Miglio2
Virology Journal201411:190

https://doi.org/10.1186/s12985-014-0190-3

Received: 28 July 2014

Accepted: 26 October 2014

Published: 21 November 2014

Abstract

Background

Breast cancer is one of the most important neoplasia among women. To reduce its incidence and mortality impact it would be desirable to early identify risk factors associated with its development. It was recently suggested that biological agents could be the etiological cause, particularly Human Papilloma Virus (HPV). No specific relationship with different breast cancer types has been demonstrated until now. In particular, the triple-negative breast cancer (TNBC), characterized by a receptor negative pattern (ER/PgR/HER2–negative) and poor prognosis, can represent one of the most relevant clinical and public health priority in terms of observational research.

Findings

Aim of the study was to evaluate the HPV-positivity prevalence in two breast cancer series (TNBC vs. non-TNBC) in Northern Sardinia, Italy. The sample size of each group was represented by 40 formalin-fixed and paraffin-embedded specimens. The mean age was 60.3 years. The majority of the cancers were ductal (84%). The grading distribution was different: G2 was the most prevalent grade in the non-TNBC series, whereas G3 was the most frequent in the TNBC series (70% and 72%, respectively). Six biological samples were HPV-positive (7.5%): the positivity was assessed only in the TNBC group (15%; p-value: 0.026). The isolated genotypes were: 16, 31, 45, 52, 6, and 66. Only one co-infection was found (i.e., HPV-6 and -66).

Conclusions

The prevalence of HPV-positivity in TNBC specimens was 15%. On the basis of its carcinogenetic ability, an etiological role in the pathogenesis of the cancer could be supposed. This association should be confirmed with longitudinal studies to better assess the role of the HPV infection in TNBC and non-TNBC tumors.

Findings

Breast cancer is the most common cancer and the principle cause of death from cancer in women worldwide [1]. Although reduction of global mortality might be achieved with early diagnosis selecting individuals on the basis of well-known risk factors (i.e., age, familial history, and a previous history of breast cancer), the majority of the cases in low- and middle-income countries cannot be diagnosed with a secondary prevention strategy. Moreover, risk factors may be not recognized in a large proportion of patients [2]. Therefore, it is crucial to confirm the role of other suspected risk factors, such as viral infections due to Epstein-Barr virus, mouse mammary tumor virus, and human papilloma virus (HPV). To date, the relationship between HPV and breast cancer has not been fully elucidated: sexual transmission, by direct contact with genital region, and/or hematological spread [3] from genital lesions should be considered. The potential causal association between HPV infection and breast cancer was firstly described in 1992 [4]; however, some Authors confirmed the relationship in association with different HPV prevalence estimates [5]-[10] but others did not [11]-[13]. Incongruous findings may depend on the assay methods, HPV prevalence, and geographic differences [14]-[16]; besides, very few studies evaluated the association between HPV infection and breast cancer clinical-pathologic features, such as histologic subtypes, tumor grade, hormone receptors expression and Human Epidermal Growth Factor Receptor 2 (HER2) status [17]-[19].

In clinical practice, according to a recent molecular classification, immunohistochemical expression of Estrogen (ER) and Progesterone (PgR) receptors and HER2 allows to categorize breast cancers in different prognostic subgroups (luminal A, luminal B, HER2 overexpressing, and triple negative breast cancers [TNBC]), with distinct therapeutic approaches [20]. In particular, the TNBC phenotype (ER/PgR/HER2–negative), which accounts for 10-24% of invasive breast cancers, is characterized by earlier onset, poor prognosis, and limited therapeutic options [3], therefore, it may represent a priority epidemiological research target [21].

Recently, our group performed a case–control investigation, which described a high overall prevalence of HPV cervical infection in women living in Northern Sardinia, Italy. In particular, HPV types −16 and −51 DNA were detected in 12.5 and 6.3% of atypical squamous cells of undetermined significance; 24.0% and 16.0% of low-grade squamous intraepithelial lesions; 50.0% and 50.0% of high-grade squamous intraepithelial lesions, respectively [22]. Moreover, these figures were confirmed by a further retrospective study in embedded invasive cervical cancers, which highlighted the primary role of HPV-16 in the pathogenesis of cervical carcinoma followed by an unusual high prevalence of HPV-51 infection (36.2%) [23]. The recent availability of two HPV vaccines, recommended for the primary cervical cancer prevention, could imply the potential advantage of immunization practices in preventing other HPV-related cancers.

On this basis, we carried out a case–control study aimed at identifying the presence of HPV-DNA in embedded tissues series of TNBC diagnosed in women from Northern Sardinia.

Ethical approval and informed consent for this study was unnecessary, according to the Italian legislation concerning the guidelines for the performance of observational studies (G.U. n. 76. 31-3-2008). However, a formal approval of the study protocol was requested in 2013 to the Ethical Committee of the Azienda Sanitaria Locale n°1 of Sassari, Italy (PN-1137/L 2013).

A case–control study, based on a case–control design, was performed to evaluate the prevalence of HPV infection in a subset of 40 embedded TNBC and 40 embedded non-TNBC, as controls; both groups of breast cancer series belonged to women admitted to a tertiary University Hospital located in Sassari, Italy.

An ad-hoc case report form was created to record demographic, histopathological and virological information. Data were anonymized in compliance with the Law Decree No. 196/2003, article 24 (Code for the protection of personal data).

Based on a sample size calculation, 40 formalin-fixed and paraffin-embedded (FFPE) tissues from TNBC specimens were consecutively and retrospectively selected from the pool of those collected in the Pathology Unit, Department of Clinical and Experimental Medicine, University of Sassari. The selection of every TNBC specimen was associated with a FFPE non-TNBC specimen, as control, paired by age (±5 years). The enrolled series was diagnosed by a pathologist who was blinded to the final diagnosis. The same methodological blinding procedure was followed for the virological analysis, carried out in triplicate at the WHO quality-assured laboratory of the Hygiene and Preventive Medicine Unit, Department of Biomedical Sciences, University of Sassari (http://www.who.int/biologicals/areas/vaccines/hpv_labnet/en/).

Ten consecutive sections, 10 micron in thickness, were cut under sterile conditions from representative neoplastic tissue blocks of 80 breast cancers, in order to obtain genomic DNA. Nucleic acids were extracted with a commercially available extraction kit (QIAamp DNA FFPE Tissue Kit, Qiagen, Hilden, Germany) in accordance with the manufacturer’s instructions. To obtain genomic DNA 10ul of RNase A (20 mg/ml, Rnase PureLink, Life Technologies) were applied directly to the silica membrane to digest contaminating RNA. The quantity and the quality of nucleic acids were assessed spectrophotometrically (260 nm, 260/280 and 260/230 ratios, spectrum 220–320 nm) using Nanodrop ND1000 (EuroClone, Milan, Italy). Positive and negative controls were represented by HPV-positive samples and water blanks, respectively HPV DNA sequences were detected with the INNO-LiPA HPV Genotyping Extra kit (Innogenetics, Gent, Belgium), based on the reverse hybridization principle, according to manufacturer’s instructions. The INNO-LiPA assay covers all currently known high-risk HPV genotypes, such as high-risk (HPV 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82), low-risk HPV genotypes (HPV 6, 11, 40, 43, 44, 54, 70), and some additional types (HPV 69, 71, 74), while HPV 13, 34 and 67 genotypes are interpreted as HPV X. The INNO-LiPA assay utilizes a cocktail of biotinylated consensus primers (SPF10) to amplify a 65-bp region within the L1 Open Reading Frame of multiple HPV types. The biotinylated PCR products are then genotyped by hybridization to HPV type-specific oligonucleotide probes bound to nitrocellulose membranes and detected by an alkaline phosphatase-streptavidin conjugate and colorimetric detection. Post-PCR hybridization and colorimetric detection were performed using the Auto-LiPA 48 instrument in accordance with the manufacturer’s recommendations. At the end of color development, the strips were scanned and evaluated by the Line Reader and Analysis software (LiRAS) to determine if defined bands for a particular genotype probe were visible. A biological sample is considered HPV positive if at least one of the type-specific lines or one of the HPV control lines is positive. An additional primer pair for the amplification of the human HLA-DPB1 gene is added to monitor sample quality and extraction. When positivity for HR genotypes −16, −18, −31, −45, −51, and −52 was found, confirmation was obtained testing biological samples with an “in-house” Real-Time quantitative TaqMan PCR assay [11],[22].

The sample size, calculated considering a first type error of 0.05, based on a case control ratio of 1:1, and an estimated exposure prevalence of 0.134, computed pooling proportions of 7 studies conducted in Europe [12], with a statistical power of 0.8 for an OR≥4, required 40 cases. Qualitative variables were summarized with percentages and were statistically compared using the z-proportion hypothesis test. Chi-square or Fisher exact test was used when appropriate. A p-value <0.05 was considered statistically significant. Statistical analysis was carried out using the statistical software Stata 11.0 (StataCorp LP, College Station, Texas).

A total of 80 embedded breast cancer specimens were analyzed: 40 were TNBC and 40 were embedded non-TNBC, namely 38 “luminal A” and 2 “HER2 overexpressing” variants. The mean (standard deviation) age of the patients was 60.3 (14.2) years; in particular, it was 60.3 (15.8) and 60.3 (12.6) for TNBC cases and controls, respectively (p-value: 0.99). Patients’ characteristics and pathology features are described in Table 1.
Table 1

Demographic, pathological, and virological characteristics of the selected cohort

Variables

n = 80

Triple-negative

Other receptor pattern

p-value

(n = 40)

(n = 40)

Mean age (SD), years

60.3 (14.2)

60.3 (15.8)

60.3 (12.6)

0.99

Histotype, n (%)

Invasive ductal

67 (83.8)

31 (77.5)

36 (90.0)

0.11

Invasive lobular

5 (6.3)

2 (5.0)

3 (7.5)

Others

8 (10.0)

7 (17.5)

1 (2.5)

Grading, n (%)

1

6 (7.6)

0 (0.0)

6 (15.0)

<0.0001

2

39 (49.4)

11 (28.2)

28 (70.0)

3

34 (43.0)

28 (71.8)

6 (15.0)

HPV+, n (%) [CI 95%]

6 (7.5) [1.7-13.3]

6 (7.5) [1.7-13.0]

0 (0.0) [0.0-0.0]

0.026

SD: Standard Deviation.

CI: Confidence Interval.

According to histopathological classification, the majority of the cancers were ductal (67, 83.8%), followed by lobular (5, 6.3%), and others (8, 10%). The proportional grading distribution in the entire series was the following: G1 7.6% (n = 6), G2 49.4% (n = 39), and G3 43.0% (n = 34); in particular, G1 0.0% (n = 0), G2 28.2% (n = 11), and G3 71.8% (n = 28) for the TNBC cases; conversely, the proportion for the non-TNBC controls was G1 15.0% (n = 6), G2 70.0% (n = 28), and G3 15.0% (n = 6) (p-value <0.0001).

Out of 80 patients six (7.5%, 95% confidence intervals: 1.7-13.0) were positive for at least one HPV genotype. In particular, HPV positivity was detected only among the 40 TNBC (15.0%; p-value = 0.026). The most frequent genotypes were HPV-16 (28.6%), −31 (14.3%), −45 (14.3%), −52 (14.3%), −6 (14.3%), −66 (14.3%); the only co-infection detected was HPV-6 and HPV-66.

Logistic regression analysis did not identify covariates associated with HPV-positivity (results not showed).

HPV genome was detected in approximately 8% of the cases suggesting a viral pathogenesis of the cancer on the basis of its well known role in the carcinogenesis of the epithelial cells [14], even if the proportion found was below the average value assessed by other Authors [16],[19]. However, the study we performed was not designed to evaluate the prevalence, being a case–control study, but to focus on the relationship between HPV infection and TNBC and to demonstrate its potential etiopathogenetic role in this kind of tumors.

The difference in terms of cellular differentiation was striking: the proportion of G3 was significantly higher in the TNBC group than in the non-TNBC category. However, no differences for the histological type were found, since the majority of the carcinomas showed ductal differentiation.

TNBC were the most undifferentiated carcinomas: they were the only neoplastic type found positive to the molecular analysis aimed at diagnosing HPV DNA. The non-TNBC series were HPV negative, and the difference in terms of positivity was statistically significant.

A more prevalent genotype was not identified: those detected were genotypes usually identified in the geographical context where this epidemiological study was carried out [22],[23].

Even if the study carried out in our center detected only HPV-positivity in the TNBC, the probability of virological positive results in other cancers showing different receptor patterns could be hypothesized (e.g., [10]). Nevertheless, other studies confirmed that HPV-positivity can be frequently found in estrogen-receptor negative tumors or in those characterized by a high proliferation rate [9].

At our best knowledge, our research is one of the first observational studies proving an association between TNBC phenotype and HPV-positivity. Moreover, our findings strengthen the hypothesis of an association between HPV-positivity and poorly differentiated variants. Therefore, our results, which can represent the basis for future studies, should be carefully evaluated because only a few HPV positive cases were identified and other studies found HPV in breast tissues with estrogen-receptor expression [24]. Moreover, the low viral load, detected in several studies [25],[26], can explain the low frequency of HPV-positive series.

Furthermore, the explanation of the role played by the host susceptibility will be necessary, proving if the genetic background can predispose to an imbalance of the native and/or adaptive immunity favoring the infection in that specific anatomical area, as well as the activation of an uncontrolled proliferation cycle.

The demonstration of the etiologic role of the HPV infection could be relevant, particularly because of the availability of highly efficacious preventive vaccines; in case of a research concordance on the role of HPV, this primary prevention strategy could increase the armamentarium of the current tools implemented in the breast cancer prevention.

This study shows some limitations. Its retrospective nature cannot assess if HPV infection precedes the cancer development. However, the epidemiological nature of the study, i.e. the case/control design, is the one suggested in case of rare events. The sample size is smaller than the statistical population size but, in order to avoid unreliable results related to unpowered studies, we computed the hypothesized sample size representative of the current population on the basis of several epidemiology-based assumptions. Furthermore, we could not assess the pathogenetic role of the HPV genotypes: new molecular hybridization in situ studies are needed to evaluate the cellular location and the pattern of hybridization of the HPV genome, that is to evaluate if the HPV-DNA is integrated in the human DNA or shows episomal replication in the neoplastic nuclei. It is straightforward that the integration in the human genome can alter the control of the cellular duplication cycle. Another study we are performing will try to answer to that relevant pathogenetic issue. The risk of a cross-contamination was avoided adopting sterile procedures during the preparation of the biological samples; the methodological efficacy of the molecular procedures was indirectly demonstrated by the detection of six different genotypes out of six positive TNBC samples.

Another unsolved problem is the origin of the HPV: to understand the original site of infection is important for the identification of preventive measures. On this basis, a concomitant virological study on cervical and/or oral-laryngeal samples could have allowed to appreciate if the sexual transmission has a role in the human spread of HPV types [14]. Unfortunately, the missing systematic cervical cancer screening of the patients in Sardinia did not allow the detection of HPV infection in other anatomical sites for the individuals enrolled in our study.

It is clear that the immunization programs, carried out in young adults, could play a role in the near future in the protection against those genotypes involved in the cancer pathogenesis and included in the currently available vaccines. However, the low prevalence of HPV suggests that other epidemiological, demographic (e.g., genetic background), clinical, virological risk factors should be assessed to better understand the potential synergistic or additive pathogenetic role of HPV genotypes.

Authors’ contributions

AFP PACR MRM and MRDM were involved in the coordination and design of the study. PACR selected and reviewed the histopathological aspect of all BC sample included in the study. AFP carried out the HPV-DNA search in TNBC and no-TNBC samples. MRM and MRDM carried out molecular analysis. GS and PC performed statistical analysis. All authors helped draft the manuscript and the final version was approved by all authors.

Abbreviations

HPV: 

human papilloma virus

HER2: 

Human Epidermal Growth Factor Receptor 2

ER: 

Estrogen receptor

PgR: 

Progesterone receptor

TNBC: 

Triple-negative breast cancer

FFPE: 

formalin-fixed and paraffin-embedded

LiRAS: 

Line Reader and Analysis software

Declarations

Acknowledgments

We would like to thank the Fondazione Banco di Sardegna for providing funding for the project.

Authors’ Affiliations

(1)
Hygiene and Preventive Medicine, Department of Biomedical Sciences, University of Sassari
(2)
Department of Clinical and Experimental Medicine, University of Sassari
(3)
Epidemiology and Medical Statistics Unit, Department of Biomedical Sciences, University of Sassari - Research, Medical Education and Professional Development Unit, AOU Sassari
(4)
Surgical Pathology Unit, Department of Diagnostic Services, ASL Olbia

References

  1. World Health Organization: Breast cancer: prevention and control. [cited 2014 May 21]; Available from: , [http://www.who.int/cancer/detection/breastcancer/en/]
  2. Anders CK, Carey LA: Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer. 2009, 9 (Suppl 2): S73-S81. 10.3816/CBC.2009.s.008.PubMedPubMed CentralView ArticleGoogle Scholar
  3. Foresta C, Bertoldo A, Garolla A, Pizzol D, Mason S, Lenzi A, De Toni L: Human papillomavirus proteins are found in peripheral blood and semen Cd20+ and Cd56+ cells during HPV-16 semen infection. BMC Infect Dis. 2013, 13: 593-10.1186/1471-2334-13-593.PubMedPubMed CentralView ArticleGoogle Scholar
  4. Di Lonardo A, Venuti A, Marcante ML: Human papillomavirus in breast cancer. Breast Cancer Res Treat. 1992, 21 (2): 95-100. 10.1007/BF01836955.PubMedView ArticleGoogle Scholar
  5. Akil N, Yasmeen A, Kassab A, Ghabreau L, Darnel AD, Al Moustafa AE: High-risk human papillomavirus infections in breast cancer in Syrian women and their association with Id-1 expression: a tissue microarray study. Br J Cancer. 2008, 99 (3): 404-407. 10.1038/sj.bjc.6604503.PubMedPubMed CentralView ArticleGoogle Scholar
  6. Baltzell K, Buehring GC, Krishnamurthy S, Kuerer H, Shen HM, Sison JD: Limited evidence of human papillomavirus in [corrected] breast tissue using molecular in situ methods. Cancer. 2012, 118 (5): 1212-1220. 10.1002/cncr.26389.PubMedView ArticleGoogle Scholar
  7. Heng B, Glenn WK, Ye Y, Tran B, Delprado W, Lutze-Mann L, Whitaker NJ, Lawson JS: Human papilloma virus is associated with breast cancer. Br J Cancer. 2009, 101 (8): 1345-1350. 10.1038/sj.bjc.6605282.PubMedPubMed CentralView ArticleGoogle Scholar
  8. Hennig EM, Suo Z, Thoresen S, Holm R, Kvinnsland S, Nesland JM: Human papillomavirus 16 in breast cancer of women treated for high grade cervical intraepithelial neoplasia (CIN III). Breast Cancer Res Treat. 1999, 53 (2): 121-135. 10.1023/A:1006162609420.PubMedView ArticleGoogle Scholar
  9. Kroupis C, Markou A, Vourlidis N, Dionyssiou-Asteriou A, Lianidou ES: Presence of high-risk human papillomavirus sequences in breast cancer tissues and association with histopathological characteristics. Clin Biochem. 2006, 39 (7): 727-731. 10.1016/j.clinbiochem.2006.03.005.PubMedView ArticleGoogle Scholar
  10. Pereira Suarez AL, Lorenzetti MA, Gonzalez Lucano R, Cohen M, Gass H, Martinez Vazquez P, Gonzalez P, Preciado MV, Chabay P: Presence of human papilloma virus in a series of breast carcinoma from Argentina. PLoS One. 2013, 8 (4): e61613-10.1371/journal.pone.0061613.PubMedPubMed CentralView ArticleGoogle Scholar
  11. Chang P, Wang T, Yao Q, Lv Y, Zhang J, Guo W, Wang L, Chen J: Absence of human papillomavirus in patients with breast cancer in north-west China. Med Oncol. 2012, 29 (2): 521-525. 10.1007/s12032-011-9945-5.PubMedView ArticleGoogle Scholar
  12. Hachana M, Ziadi S, Amara K, Toumi I, Korbi S, Trimeche M: No evidence of human papillomavirus DNA in breast carcinoma in Tunisian patients. Breast. 2010, 19 (6): 541-544. 10.1016/j.breast.2010.05.007.PubMedView ArticleGoogle Scholar
  13. Hedau S, Kumar U, Hussain S, Shukla S, Pande S, Jain N, Tyagi A, Deshpande T, Bhat D, Mir MM, Chakraborty S, Singh YM, Kumar R, Somasundaram K, Bharti AC, Das BC: Breast cancer and human papillomavirus infection: no evidence of HPV etiology of breast cancer in Indian women. BMC Cancer. 2011, 11: 27-10.1186/1471-2407-11-27.PubMedPubMed CentralView ArticleGoogle Scholar
  14. Simões PW, Medeiros LR, Simões Pires PD, Edelweiss MI, Rosa DD, Silva FR, Silva BR, Rosa MI: Prevalence of human papillomavirus in breast cancer: a systematic review. Int J Gynecol Cancer. 2012, 22 (3): 343-347. 10.1097/IGC.0b013e31823c712e.PubMedView ArticleGoogle Scholar
  15. Wang T, Chang P, Wang L, Yao Q, Guo W, Chen J, Yan T, Cao C: The role of human papillomavirus infection in breast cancer. Med Oncol. 2012, 29 (1): 48-55. 10.1007/s12032-010-9812-9.PubMedView ArticleGoogle Scholar
  16. Li N, Bi X, Zhang Y, Zhao P, Zheng T, Dai M: Human papillomavirus infection and sporadic breast carcinoma risk: a meta-analysis. Breast Cancer Res Treat. 2011, 126 (2): 515-520. 10.1007/s10549-010-1128-0.PubMedPubMed CentralView ArticleGoogle Scholar
  17. Joshi D, Buehring GC: Are viruses associated with human breast cancer? Scrutinizing the molecular evidence. Breast Cancer Res Treat. 2012, 135 (1): 1-15. 10.1007/s10549-011-1921-4.PubMedView ArticleGoogle Scholar
  18. Mammas IN, Sourvinos G, Zaravinos A, Spandidos DA: Vaccination against human papilloma virus (HPV): epidemiological evidence of HPV in non-genital cancers. Pathol Oncol Res. 2011, 17 (1): 103-119. 10.1007/s12253-010-9288-0.PubMedView ArticleGoogle Scholar
  19. Grenier J, Soria JC, Mathieu MC, Andre F, Abdelmoula S, Velasco V, Morat L, Besse B, Dunant A, Spielmann M, Delaloge S: Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast. Anticancer Res. 2007, 27 (1B): 547-555.PubMedGoogle Scholar
  20. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ: Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013, 24 (9): 2206-2223. 10.1093/annonc/mdt303.PubMedPubMed CentralView ArticleGoogle Scholar
  21. Carey L, Winer E, Viale G, Cameron D, Gianni L: Triple-negative breast cancer: disease entity or title of convenience?. Nat Rev Clin Oncol. 2010, 7 (12): 683-692. 10.1038/nrclinonc.2010.154.PubMedView ArticleGoogle Scholar
  22. Piana A, Sotgiu G, Castiglia P, Pischedda S, Cocuzza C, Capobianco G, Marras V, Dessole S, Muresu E: Prevalence and type distribution of human papillomavirus infection in women from North Sardinia. Italy. BMC Public Health. 2011, 11: 785-10.1186/1471-2458-11-785.PubMedView ArticleGoogle Scholar
  23. Piana A, Sotgiu G, Cocuzza C, Musumeci R, Marras V, Pischedda S, Deidda S, Muresu E, Castiglia P: High HPV-51 prevalence in invasive cervical cancers: results of a pre-immunization survey in North Sardinia, Italy. PLoS One. 2013, 8 (5): e63395-10.1371/journal.pone.0063395.PubMedPubMed CentralView ArticleGoogle Scholar
  24. Ohba K, Ichiyama K, Yajima M, Gemma N, Nikaido M, Wu Q, Chong P, Mori S, Yamamoto R, Wong JE, Yamamoto N: In vivo and in vitro studies suggest a possible involvement of HPV infection in the early stage of breast carcinogenesis via APOBEC3B induction. PLoS One. 2014, 9 (5): e97787-10.1371/journal.pone.0097787.PubMedPubMed CentralView ArticleGoogle Scholar
  25. Khan NA, Castillo A, Koriyama C, Kijima Y, Umekita Y, Ohi Y, Higashi M, Sagara Y, Yoshinaka H, Tsuji T, Natsugoe S, Douchi T, Eizuru Y, Akiba S: Human papillomavirus detected in female breast carcinomas in Japan. Br J Cancer. 2008, 99 (3): 408-414. 10.1038/sj.bjc.6604502.PubMedPubMed CentralView ArticleGoogle Scholar
  26. Herrera-Romano L, Fernández-Tamayo N, Gómez-Conde E, Reyes-Cardoso JM, Ortiz-Gutierrez F, Ceballos G, Valdivia A, Piña P, Salcedo M: Absence of human papillomavirus sequences in epithelial breast cancer in a Mexican female population. Med Oncol. 2012, 29 (3): 1515-1517. 10.1007/s12032-011-0059-x.PubMedView ArticleGoogle Scholar

Copyright

© Piana et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.